Related Experiment Video
Updated: May 26, 2025
Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
An experimental study on the lytic bacteriophage MSP15 with wide-spectrum targeting methicillin-resistant
Peijun Lin1, Suling Liu2, Zhi Cao3
1Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
Background:
Methicillin-resistant Staphylococcus aureus (MRSA) is identified as one of the main drug-resistant pathogens, increasing the risk of no antibiotic availability in clinical settings and necessitating the urgent search for alternative antibacterial treatments. Phage therapy has been proposed as a therapeutic approach for bacterial infections, offering numerous advantages and broad application prospects. However, the efficacy of phage therapy in treating drug-resistant infections in humans remains uncertain. Given the current advances in phage therapy and the grim situation posed by MRSA infections, the application of lytic bacteriophages with wide-spectrum activity to treat difficult MRSA infections is proposed.
Objective:
The objective is to isolate, purify, and screen lytic bacteriophages targeting MRSA from the environment and to assess their efficacy and safety through in vitro and in vivo experiments, with the aim of providing another therapy for MRSA infection.
Methods:
Firstly, representative MRSA strains were selected, and their corresponding phages were isolated and purified from hospital sewage. Secondly, the isolated phages were screened to identify lytic bacteriophages with broad-spectrum activity, and their biological characteristics were analyzed. Thirdly, a systemic infection mouse model was established to evaluate the efficacy and safety of phage MSP15 against MRSA infection.
Results:
In this study, Staphylococcus aureus Phage MSP15, a lytic bacteriophage with broad-spectrum activity targeting MRSA, was successfully isolated, purified and screened. Furthermore, in the systemic infection mouse model, administration of phage MSP15 led to prolonged survival time of MRSA-infected mice. A 100% survival rate was observed in infected mice with both immediate and delayed administration of high doses of phage MSP15 (MOI = 1), although efficacy may potentially be reduced with delayed treatment compared to immediate treatment. Additionally, an immune response was induced by phage MSP15, resulting in the production of IgG against phage MSP15, while no adverse events such as changes in core body temperature, allergic reactions, or other adverse effects were observed in mice.
Conclusion:
Lytic bacteriophages with a wide spectrum can become an auxiliary approach for treating MRSA infection.
Insights
Lytic bacteriophages show promise in combating Methicillin-resistant Staphylococcus aureus (MRSA) infections. Phage MSP15 demonstrated efficacy and safety in a mouse model, offering a potential new therapy for drug-resistant bacterial infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Bacteriophage Therapy
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) is a major drug-resistant pathogen, driving the need for alternative antibacterial treatments.
- Phage therapy presents a promising therapeutic strategy for bacterial infections, but its efficacy against drug-resistant strains requires further investigation.
- Lytic bacteriophages with broad-spectrum activity are proposed as a viable option for treating challenging MRSA infections.
Purpose of the Study:
- To isolate, purify, and screen lytic bacteriophages effective against MRSA.
- To evaluate the efficacy and safety of these phages through in vitro and in vivo studies.
- To establish phage therapy as a potential alternative treatment for MRSA infections.
Main Methods:
- MRSA strains were selected, and lytic phages were isolated and purified from hospital sewage.
- Isolated phages were screened for broad-spectrum activity and biological characteristics.
- A systemic infection mouse model was used to assess the efficacy and safety of phage MSP15.
Main Results:
- Phage MSP15, a lytic bacteriophage with broad-spectrum activity against MRSA, was successfully isolated and purified.
- Administration of phage MSP15 significantly prolonged survival time in MRSA-infected mice, with a 100% survival rate at high doses.
- Phage MSP15 induced an immune response (IgG production) without observable adverse effects in mice.
Conclusions:
- Lytic bacteriophages with broad-spectrum activity can serve as an auxiliary treatment for MRSA infections.
- Phage MSP15 is a safe and effective therapeutic candidate for MRSA infections.
- Further research into phage therapy can provide novel solutions for combating antibiotic resistance.
